Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pearl tops the week's venture financing

This article was originally published in Scrip

Executive Summary

Venture financing deals worth more than $106 million were recorded by Medtrack last week, with Pearl Therapeutics of California topping the table by raising $65 million in a series D round led by Vatera Healthcare Partners (, 14 November 2012). The company will use the proceeds to begin Phase III trials of its LAMA/LABA metered dose inhaler-delivered product for chronic obstructive pulmonary disease (COPD).



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts